Zentalis Pharmaceuticals Inc (ZNTL) concluded trading on Thursday at a closing price of $2.39, with 3.41 million shares of worth about $8.15 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.29% during that period and on January 16, 2025 the price saw a loss of about -16.14%. Currently the company’s common shares owned by public are about 71.15M shares, out of which, 56.61M shares are available for trading.
Stock saw a price change of -14.03% in past 5 days and over the past one month there was a price change of -22.65%. Year-to-date (YTD), ZNTL shares are showing a performance of -21.12% which decreased to -82.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.41 but also hit the highest price of $18.07 during that period. The average intraday trading volume for Zentalis Pharmaceuticals Inc shares is 1.33 million. The stock is currently trading -18.86% below its 20-day simple moving average (SMA20), while that difference is down -27.35% for SMA50 and it goes to -58.73% lower than SMA200.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) currently have 71.15M outstanding shares and institutions hold larger chunk of about 83.18% of that.
The stock has a current market capitalization of $170.33M and its 3Y-monthly beta is at 1.86. It has posted earnings per share of -$2.53 in the same period. It has Quick Ratio of 7.29 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZNTL, volatility over the week remained 13.13% while standing at 9.35% over the month.
Stock’s fiscal year EPS is expected to rise by 45.10% while it is estimated to decrease by -19.28% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on August 12, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by UBS stated Zentalis Pharmaceuticals Inc (ZNTL) stock as a Neutral in their note to investors on June 20, 2024, suggesting a price target of $5 for the stock. On June 18, 2024, Wells Fargo Downgrade their recommendations, while on June 18, 2024, Wedbush Downgrade their ratings for the stock with a price target of $4. Stock get an Equal-weight rating from Morgan Stanley on June 18, 2024.
